Drug Price Transparency
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug company moving patients to a new reformulated version of a drug when an existing drug’s exclusivity is close to expiring.
The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases for prescription drugs.
A recent report from UnitedHealth comparing specialty drug spending in hospitals and independent physician offices fails to account for critical differences between these two settings while also ignoring the chief culprit in the growth in drug spending – the drug companies themselves.
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
A federal judge yesterday struck down a Centers for Medicare & Medicaid Services final rule requiring drug companies to include list prices in direct-to-consumer television advertisements of products for which Medicare and Medicaid reimbursement is available.
The White House June 24 released an executive order on “improving price and quality transparency in American health care.” The executive order focuses on five policies:
The House Energy and Commerce Subcommittee on Health today held a hearing on seven bills aimed at improving transparency in the drug supply chain to lower prices.
The Centers for Medicare & Medicaid Services May 16 released a final rule with the intent of lowering drug prices for beneficiaries enrolled in Medicare Advantage and Part D programs.
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released today by the Campaign for Sustainable Rx Pricing.